JP4746258B2 - 薬剤 - Google Patents

薬剤 Download PDF

Info

Publication number
JP4746258B2
JP4746258B2 JP2002592909A JP2002592909A JP4746258B2 JP 4746258 B2 JP4746258 B2 JP 4746258B2 JP 2002592909 A JP2002592909 A JP 2002592909A JP 2002592909 A JP2002592909 A JP 2002592909A JP 4746258 B2 JP4746258 B2 JP 4746258B2
Authority
JP
Japan
Prior art keywords
lipoic acid
ambroxol
thiol
salt
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002592909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004531567A (ja
JP2004531567A5 (enExample
Inventor
ミヒャエル テーゲル
ジークフリート アンゾルゲ
ゲールハルト フリース
ディーター コーグス
Original Assignee
エスパルマ ゲーエムベーハー
イーエムティーエム ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスパルマ ゲーエムベーハー, イーエムティーエム ゲーエムベーハー filed Critical エスパルマ ゲーエムベーハー
Publication of JP2004531567A publication Critical patent/JP2004531567A/ja
Publication of JP2004531567A5 publication Critical patent/JP2004531567A5/ja
Application granted granted Critical
Publication of JP4746258B2 publication Critical patent/JP4746258B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2002592909A 2001-05-28 2002-05-27 薬剤 Expired - Fee Related JP4746258B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10125882.8 2001-05-28
DE10125882A DE10125882B4 (de) 2001-05-28 2001-05-28 Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
PCT/EP2002/005811 WO2002096398A2 (de) 2001-05-28 2002-05-27 Arzneimittel enthaltend einen effektor des glutathionmetabolismus zussammen mit $g(a)-liponsäure im rahmen der behandlung des diabetes mellitus

Publications (3)

Publication Number Publication Date
JP2004531567A JP2004531567A (ja) 2004-10-14
JP2004531567A5 JP2004531567A5 (enExample) 2009-08-20
JP4746258B2 true JP4746258B2 (ja) 2011-08-10

Family

ID=7686361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002592909A Expired - Fee Related JP4746258B2 (ja) 2001-05-28 2002-05-27 薬剤

Country Status (9)

Country Link
US (1) US7429614B2 (enExample)
EP (2) EP1529529B1 (enExample)
JP (1) JP4746258B2 (enExample)
AT (2) ATE429911T1 (enExample)
AU (1) AU2002344178A1 (enExample)
DE (3) DE10125882B4 (enExample)
ES (2) ES2247377T3 (enExample)
PT (1) PT1529529E (enExample)
WO (1) WO2002096398A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303229B4 (de) 2003-01-28 2007-07-26 Keyneurotek Ag Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen
DE10360954B3 (de) * 2003-12-23 2005-08-18 Esparma Gmbh Verwendung von Silibinin, dessen Salzen und/oder dessen Prodrugs zusammen mit α-Liponsäure zur Behandlung chronisch obstruktiver Lungenerkrankungen
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
JP5785355B2 (ja) * 2004-11-24 2015-09-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物における生体異物物質の肝臓クリアランスを改良する方法
US20100099751A1 (en) * 2008-10-21 2010-04-22 Al-Mulla Fahd Method of treating diabetes-related vascular complications
KR20110103987A (ko) * 2008-12-01 2011-09-21 인베이스크 테라퓨틱, 인크. 레닌-안지오텐신 알도스테론계 억제제 및 리포산 화합물을 포함하는 조성물, 및 레닌-안지오텐신 알도스테론계 관련 질환의 치료를 위한 이의 용도
CN113244265B (zh) * 2021-03-23 2023-07-14 武汉广行科学研究有限公司 配体修饰的硫化锌纳米粒子、制备方法及其在治疗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03169813A (ja) * 1989-11-09 1991-07-23 Asta Pharma Ag 細胞保護作用を有する疼痛及び炎症性疾患及び／又はレトロウイルスに起因する病気の治療用医薬並びにその製法
DE4218572A1 (de) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
DE4343593C2 (de) * 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
DE4420102A1 (de) * 1994-06-09 1995-12-14 Asta Medica Ag Arzneimittelkombinationen aus alpha-Liponsäure und herz-kreislaufaktiven Substanzen
GB9715444D0 (en) * 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
US6133304A (en) * 1997-12-23 2000-10-17 Warner-Lambert Company ACE inhibitor-MMP inhibitor combinations
DE19806354B4 (de) * 1998-02-10 2004-09-16 Bdd Group Holding Ag Verwendung von α-Liponsäure oder deren physiologisch verträgliche Salze zur Behandlung von LDL-Hypercholesterinämie
JP2000309543A (ja) * 1999-04-28 2000-11-07 Ajinomoto Co Inc 抗糖尿病剤
DE10125883A1 (de) * 2001-05-28 2002-12-12 Serumwerk Bernburg Ag Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie

Also Published As

Publication number Publication date
ES2322257T3 (es) 2009-06-18
ES2247377T3 (es) 2006-03-01
DE10125882A1 (de) 2002-12-12
JP2004531567A (ja) 2004-10-14
WO2002096398A3 (de) 2003-02-27
EP1392288A2 (de) 2004-03-03
AU2002344178A1 (en) 2002-12-09
DE50204093D1 (de) 2005-10-06
ATE429911T1 (de) 2009-05-15
EP1529529B1 (de) 2009-04-29
ATE303145T1 (de) 2005-09-15
DE10125882B4 (de) 2007-03-29
US20040138311A1 (en) 2004-07-15
PT1529529E (pt) 2009-05-11
DE50213511D1 (de) 2009-06-10
EP1529529A1 (de) 2005-05-11
EP1392288B1 (de) 2005-08-31
US7429614B2 (en) 2008-09-30
WO2002096398A2 (de) 2002-12-05

Similar Documents

Publication Publication Date Title
Ballatori et al. Glutathione dysregulation and the etiology and progression of human diseases
PL186714B1 (pl) Kompozycja farmaceutyczna do regulowania stężenialipidów do ssaka
CA3126264A1 (en) A method for side effect reduction in the use of statins via physiologically synthesized glutathione
SK286854B6 (sk) Použitie statínového liečiva na prípravu lieku na liečenie diabetickej neuropatie
CZ20031167A3 (cs) Prostředky a způsoby pro snižování plasmatického lipoproteinu(a) a rizika kardiovaskulárních onemocnění
JP4746258B2 (ja) 薬剤
JP4245926B2 (ja) α−リポ酸と一緒にグルタチオン代謝のエフェクターを含有する腎臓代償療法の分野における医薬品
JPH08511253A (ja) アンギオテンシン変換酵素阻害剤とａ▲ｉｉ▼アンタゴニストとの組み合わせ
TW200305570A (en) Pharmaceutical composition for regeneration of cirrhotic liver
US20140275257A1 (en) N-acetyl cysteine compositions in the treatment of systemic lupus erythematosus
US20120220659A1 (en) Medicament having promoting action on hepatocyte proliferation
JP4813183B2 (ja) Ａｂｃａ１安定化剤
HK1063606B (en) Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy
US20080275081A1 (en) Novel thrombomodulin expression promoters
CN115919831B (zh) 苯甲酸酯类化合物在抑制尿酸转运体蛋白1的活性及制备治疗高尿酸血症的药物中的应用
WO2005077399A1 (ja) 慢性閉塞性肺疾患の予防ないし治療剤
WO1998051313A1 (fr) Remedes contre les yeux secs
JP4838728B2 (ja) 慢性閉塞性肺疾患の処置のための、α‐リポ酸を伴う少なくとも１つのグルタチオン代謝のエフェクターの使用
TW202327566A (zh) 包含藻褐素及小分子褐藻醣膠之組合物用於製備治療或改善慢性腎病之醫藥品的用途及包含藻褐素、小分子褐藻醣膠及左旋肉鹼之組合物及包含其的醫藥品
HK1139586A (en) Drug having effect of promoting hepatocyte growth

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090403

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090605

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090701

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110426

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110513

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140520

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees